Truist Financial and Leerink Partners raised price objectives for Eli Lilly and Company stock.
1 report, 1 independent
Updated Sep 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Truist Financial and Leerink Partners raised price objectives for Eli Lilly and Company stock.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
Truist Financial
American bank holding company, formerly known as BB&T Corporation
- MarketBeat aggregates data on Inventiva's stock, and Truist Financial has started coverage of the company.
- Bank of America boosted its price target and gave a buy rating for Guardian Pharmacy Services, Inc. on September 15, 2026. Truist Financial also boosted its target price and gave a buy rating on the same day.
-
Leerink partners
U.S. investment bank
Related events
- Royal Bank of Canada raised price objectives and Truist Financial boosted price targets for Ingram Micro on August 1, 2026.
- Analyst firm Leerink partners raised the price target for Roivant based on share count forecast on August 13, 2025.
- Truist Financial boosted its price objective on Match Group stock.
- Leerink raised its price target for UnitedHealth Group stock.
- Truist Financial increased its price objective while First Citizens BancShares disclosed sales with the SEC.